In this MasterClass, Dr. Eric Donnenfeld discusses the applications of pharmaceutical presbyopia treatment options and the types of patients who would have the greatest benefit from these technologies.
Supported by unrestricted educational grants from Johnson & Johnson Vision and Visus Therapeutics.
Upon completion of this activity, the participant should be able to:
Jointly Provided by Evolve Medical Education and The Fundingsland Group.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Evolve Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Eric Donnenfeld, MD, FAAO
Ophthalmic Consultants of Long Island
Garden City, NY
Clinical Professor of Ophthalmology NYU
New York, NY
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Eric Donnenfeld, MD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro, Allergan, Alcon, Avellino Labs, Bausch & Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, CRST, Blephex, BVI, Dompe, ELT Sight, EyePoint Pharma, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala, Katena, Lacripen, LayerBio, LensGen, Mati Pharmaceuticals, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocuhub, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Omeros, Oyster Point Therapeutics, Pfizer, Pogotec, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharmaceutical Industries, Surface, Tarsus, Tearlab, TearScience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus. Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharma, Glaukos, Ivantis, Lacripen, LayerBio, LensGen, Mati Pharmaceuticals, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations, Oculis, Orasis Pogotec, RegenerEyes, ReTear, and RPS.
The Evolve and The Fundingsland Group staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Johnson & Johnson Vision, or Visus Therapeutics.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Eric D. Donnenfeld, MD
Marjan Farid, MD
Jason J. Jones, MD
Eva I. Liang, MD, FACS
Carlton Yuen, MD
